Company profile: Solid Biosciences
1.1 - Company Overview
Company description
- Provider of gene therapy candidates and research focused on rare genetic diseases, including SGT-003 for Duchenne muscular dystrophy, SGT-501 for catecholaminergic polymorphic ventricular tachycardia, and AVB-401 for BAG3-mediated dilated cardiomyopathy.
Products and services
- SGT-003: An investigational gene therapy candidate for Duchenne muscular dystrophy, engineered by Solid Biosciences to pursue therapeutic treatment specifically targeting DMD pathology and disease burden
- AVB-401: A research-stage gene therapy candidate for BAG3-mediated dilated cardiomyopathy, developed to address cardiomyopathy linked to BAG3 mechanisms with intended therapeutic genetic intervention
- SGT-501: A pipeline-stage gene therapy candidate for catecholaminergic polymorphic ventricular tachycardia (CPVT), created to treat CPVT with prospective genetic treatment for this cardiac condition
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Solid Biosciences
Focus Diagnostics
HQ: United States
Website
- Description: Provider of molecular and immunodiagnostic products and platforms for hospitals and commercial laboratories worldwide. Offers Simplexa molecular chemistries, HerpeSelect type-specific serology, and DxSelect IFA/ELISA kits for diseases such as West Nile Virus and Rickettsia, plus Luminex LTG, LIAISON PLEX multiplexing (including Respiratory Flex Assay), and LIAISON XL/XS automated CLIA assays.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Focus Diagnostics company profile →
ActX
HQ: United States
Website
- Description: Provider of genomic screening and pharmacogenomic services that help physicians personalize prescriptions, identify hereditary risks, understand carrier status, and adjust dosing based on drug-genome interactions. Offers GenoACT clinical decision support integrating genetic data into EHRs with real-time alerts, plus medical genetic interpretation of 23andMe raw data.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ActX company profile →
AltheaDx
HQ: United States
Website
- Description: Provider of molecular diagnostics and PCR-based services, including molecular biomarker discovery, assay development and validation, prospective/retrospective clinical trial testing, and gene expression and genotyping analysis for pre-clinical and clinical applications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AltheaDx company profile →
Great Plains Laboratory
HQ: United States
Website
- Description: Provider of research-based clinical laboratory tests for nutritional and metabolic factors in chronic illnesses, including autism, AD(H)D, fibromyalgia, and gastrointestinal and neuropsychiatric disorders. Offers urine- and stool-based profiles like OAT, GI360, MycoTOX, TOXDetect, Glyphosate Test, and IgG Food MAP to assess gut health, toxins, pathogens, and food sensitivities.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Great Plains Laboratory company profile →
Celula
HQ: United States
Website
- Description: Provider of diagnostic testing services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Celula company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Solid Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Solid Biosciences
2.2 - Growth funds investing in similar companies to Solid Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Solid Biosciences
4.2 - Public trading comparable groups for Solid Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →